Acc2014 5

• 1. Date of preparation April 2014 BRI001081ACC.14Annual ScientificSessions of theAmerican College ofCardiologyWashington DC29-31 March 2014

2. Date of preparation April 2014 BRI001081Disclaimer AstraZeneca abides by the Medicines Australia Code of Conduct (Edition 17) andAstraZeneca Global Policies, and as such will not engage in the promotion ofunregistered products or unapproved indications. These highlights have been suggested by a group of cardiologists who attendedACC.14, compiled by an external medical writer and sponsored by AstraZeneca. Statements of fact and opinions expressed are those of the speakers individually and,unless expressly stated to the contrary, are not the opinion or position of AstraZeneca.AstraZeneca does not endorse or approve, and assumes no responsibility for, thecontent, accuracy, or completeness of the information presented. Presentations areintended for educational purposes only and do not replace independent professionaljudgement. Please refer to the appropriate approved Product Information before prescribing anyagents mentioned in these highlights. 3. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Core Valve US Pivotal Trial:Self-expanding transcatheter vssurgical aortic valve replacementCommentary:Associate Professor John YiannikasConcord Hospital, SydneyAssociate Professor Chris ZeitzQueen Elizabeth Hospital, AdelaideLate-breaking trial 4. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 5. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 6. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014Earlier Extreme risk trial: Benefits of TAVRin patients at extreme surgical risk 7. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014High risk trial 8. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 9. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 10. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 11. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 12. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 13. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 14. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 15. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 16. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 17. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 18. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 19. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 20. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 21. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 22. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 23. Date of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 24. Commentary: Associate Professor John Yiannikas,Associate Professor Chris ZeitzDate of preparation April 2014 BRI001081ACC.14Washington DC29-31 March 2014 This well-designed study, showing a mortality benefit withTAVR in patients at high surgical risk, extends earlierfindings that were restricted to patients at extreme surgicalrisk. Although there was some debate about the statisticalanalysis, which used 1-tailed rather than 2-tailed tests ofsignificance, this is a landmark study which supports TAVRin lower-risk patients. The pool of patients considered eligible for TAVR is likely toexpand incrementally in the future.